Market Overview

Genprex Provides Clinical and Corporate Update for Third Quarter 2018


(NASDAQ:GNPX), a clinical stage gene therapy company developing
a new approach to treating cancer based upon a novel proprietary
technology platform, today announced a clinical and corporate update,
and the filing of quarterly results for the third quarter ended
September 30, 2018 on Form 10-Q with the Securities and Exchange

Rodney Varner, Chairman and CEO, remarked, "Over the past quarter, we
have taken steps to advance our clinical development activities. We
extended our ability to strengthen our patent protection for our TUSC2
gene platform, expanded our collaborations and augmented our team. Most
notably, we added Jan Stevens, RN, whose expertise in clinical
operations will be invaluable as we look to expand our Phase I/II
clinical study evaluating Oncoprextm in combination with Tarceva® for
treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC)."

Julien L. Pham, MD, MPH, President and Chief Operating Officer, stated,
"We are confident in our choice of Aldevron as a plasmid manufacturing
partner and look forward to working with them to continue our clinical
trials of our immunogene therapy Oncoprex™ for the treatment on
non-small cell lung cancer."

Clinical Development and Corporate Update

  • Entered into amendments with The University of Texas MD Anderson
    Cancer Center (MD Anderson) to extend the terms of two option
    agreements between Genprex and MD Anderson pertaining the use of
    TUSC2, the active agent in Genprex's lead product candidate Oncoprex,
    in combination with immunotherapies and the development and the use of
    biomarkers to predict patient response to TUSC2 therapy.
  • Entered into an agreement with Aldevron, a leading contract
    manufacturing organization, to supply TUSC2 (Tumor Suppressor
    Candidate 2) plasmid DNA for use in Genprex's clinical development
    program evaluating Oncoprex for the treatment of NSCLC.
  • Entered into agreements with additional contract manufacturing
    organizations to assist with manufacturing scale-up and transfer of
    manufacturing processes from manufacturing facilities of the
    University of Texas MD Anderson Cancer Center to commercial facilities.
  • Appointed Jan Stevens, RN as Vice President of Clinical Operations in
    October 2018. Ms. Stevens joined the Company's Cambridge office to
    lead clinical operations and support corporate development efforts,
    focusing on expanding research and clinical development opportunities,
    including the expansion of Genprex's Oncoprex + Tarceva combination
    trial across multiple US sites.

Third Quarter 2018 Financial Update

Genprex's research and development expense was $489,689 for the three
months ended September 30, 2018 as compared to $55,517 for the three
months ended September 30, 2017. The increase in the current year period
was driven entirely by increased R&D and commercialization activities
associated with the development of our drug candidate and the
progression of our Phase I/II clinical trial at MD Anderson.

Genprex had a cash position of $10.3 million as of September 30, 2018.

Forward Looking Statements
Statements contained in this
press release that are not statements of historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because these statements are
subject to risks and uncertainties, the actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to, statements
regarding the effect of TUSC2 on cancer, either alone or in combination
with other drugs, the effect of methods for predicting patients'
response to therapy, the products and services we expect to receive from
Aldevron and contract manufacturing organizations and the effect of
those products and services on the development of Oncoprex™, statements
about Genprex's business plans, statements about the timing and success
of the Company's existing and planned clinical trials, statements about
the development of the Company's current and potential future product
candidates and statements about the Company's plans to seek regulatory
approval of its product candidates. Risks that contribute to the
uncertain nature of the forward-looking statements include: the presence
and level of TUSC2's effect on cancer; the ability of Aldevron and
contract manufacturing organizations to provide products and services to
the Company and the Company's ability to utilize those products and
services; the ability of the products and services of Aldevron and
contract manufacturing organizations to influence the development of
Oncoprex™; the effect on cancer of combining TUSC2 with immunotherapies,
EGFR inhibitors, or other drugs; whether or not Genprex will be able to
negotiate and execute final technology license agreements under the
extended options with MD Anderson; the nature and scope of protection
ultimately provided under any of the licensed patents and patent
applications should such technology license agreements be executed; the
timing, success and cost of the Company's clinical trials and planned
clinical trials of TUSC2 and Oncoprex and other potential product
candidates; the timing and success of obtaining FDA approval of Oncoprex
and the Company's other potential product candidates; the success, cost
and timing of the Company's product candidate development activities;
the Company's ability to execute on its strategy; regulatory
developments in the United States and foreign countries; and the
Company's estimates regarding expenses, future revenue and capital
requirements. These and other risks and uncertainties are described more
fully under the caption "Risk Factors" and elsewhere in Genprex's
filings and reports with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Genprex does
not undertake any obligation to update these statements to reflect any
events that occur or facts that exist after the date on which the
statements were made.

About Genprex, Inc.
Genprex, Inc. is a clinical stage gene
therapy company developing a new approach to treating cancer, based upon
a novel proprietary technology platform, including Genprex's initial
product candidate, Oncoprex™ immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex's platform technologies are designed to
administer cancer fighting genes by encapsulating them into nanoscale
hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins
that are missing or found in low quantities. Oncoprex has a multimodal
mechanism of action whereby it interrupts cell signaling pathways that
cause replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells, and
modulates the immune response against cancer cells. Oncoprex has also
been shown to block mechanisms that create drug resistance. Visit the
company's web site at
or follow Genprex on Twitter at
and Facebook at

View Comments and Join the Discussion!